Study of Glycated Haemoglobin and Lipid Profile in Patients with Diabetic Foot Ulcer

Saima Mushtaq¹, Sameena Khan², Malik Rameez Rashid³

ABSTRACT

Introduction: Diabetic foot ulcer is a major disabling complication of Diabetes Mellitus and often precedes lower extremity amputation. This study aims to evaluate the level of HbA1c and lipid profile in patients with diabetic foot ulcer as T2DM patients are prone to diabetic dyslipidemia, which puts them at risk of developing macrovascular and microvascular diseases.

Material and methods: The study was accomplished at a tertiary care hospital in Jammu & Kashmir. One hundred ten subjects with T2DM were enrolled for the present study, this included 55 subjects with DFU and 55 subjects without DFU. The HbA1c and lipid profile of the subjects were measured with standard methods.

Results: In our study HbA1c level was found higher in diabetic patients with diabetic foot ulcer when compared with patients without. Also lipid profile was found deranged in diabetic foot ulcer patients in comparison to control group. It was found that approximately 78% DFU have HbA1c levels >7%. Unlike the DFU-patients, 79% of patients without DFU have HbA1c level controlled.

Conclusion: As diabetic foot ulcer is a major disabling complication of Diabetes Mellitus and often precedes lower extremity amputation, we conclude that HbA1c level should be maintained in normal range and regulating it is imperative for avoiding T2DM complications.

Keywords: Diabetic Foot Ulcers (DFU), Glycated Haemoglobin (HbA1c), Lipid Profile, Diabetes Mellitus Type-2(T2DM).

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a group of metabolic disorder rising rapidly and leading to public health issue with noticeable effects on human health and health care systems.¹ It has been indicated from the data and statistical analysis of International Diabetes Federation (IDF) that around 425 million adults have diabetes mellitus (DM) world wide and by 2045, the number of DM patients are estimated to rise around 629 million.² As diabetic patients are prone to develop foot ulcers and if not managed properly may be followed by neurological and vascular insufficiency resulting in substantial morbidity and mortality.³,４ Foot infections are one of the long term complications of Type 2 diabetes as 1-4% of people with type 2 diabetes develop a foot ulcer each year and it can result in gangrene, lower extremity amputation.⁵ Patients with diabetes are 25 times more likely to lose a leg and up to 70% of all leg amputations occur in people with diabetes. A study by The Global Lower Extremity Amputation Study Group revealed that 25%-90% of amputations were associated with diabetes.⁶ Dyslipidemia is more prevalent in T2DM patients which in turn puts them at more risk of developing complications like stroke, coronary artery diseases, nephropathy, neuropathy, etc. HbA1c is considered as a reliable marker of glycemic control, and its level should be maintained in normal range to prevent complications in long term. HbA1c is not only a reliable glycaemic index but can also be used as an important indicator in determining the risk of diabetes-related complications and mortality.⁷⁸ The aim of this study was to check the level of HbA1c and lipid profile in patients with diabetic foot ulcer, hypothesising that elevated HbA1c predicts poor prognosis for ulcer healing in patients with diabetes.

MATERIAL AND METHODS

The study was accomplished at a tertiary care hospital in Jammu & Kashmir. One hundred ten subjects with T2DM were enrolled for the present study, this included 55 subjects with DFU and 55 subjects without DFU. The study participants were further divided into two groups based on the glycaemic control (i.e. with HbA1c ≥ 7 and HbA1c < 7). All patients with foot ulcer were included in the study. Patients on lipid-lowering drugs, steroids or having thyroid, hepatic, renal problems, sickle cell disease & endocrinopathies were excluded from the study. Those patients having history of any chronic illness or malignancy were also excluded from the study. A written informed consent was obtained from all participants and the study was conducted in accordance with the Declaration of Helsinki. ¹⁰

Biochemical Parameters

Fasting morning blood samples were collected from the patients in plain vacutainer (5ml) & ethylene diaminetetraacetic acid (2ml). Serum was separated and

¹Assistant Professor, Department of Biochemistry, Government Medical Collage& Hospital, Baramulla, ²Assistant Professor, Department of Microbiology, Dr. D.Y. Patil Medical College, Hospital & Research Centre, Pune, Maharashtra, India ³Assistant Consultant, Department of Anaesthesiology, KFMC, Riyadh, Saudi Arabia

Corresponding author: Saima Mushtaq, Assistant Professor, Department of Biochemistry, Government Medical Collage& Hospital, Baramulla, Jammu & Kashmir, India

How to cite this article: Saima Mushtaq, Sameena Khan, Malik Rameez Rashid. Study of glycated haemoglobin and lipid profile in patients with diabetic foot ulcer. International Journal of Contemporary Medical Research 2020;7(6):F1-F4.

DOI: http://dx.doi.org/10.21276/ijcmr.2020.7.6.17
Mushtaq, et al. Glycated Haemoglobin and Lipid Profile

analysed immediately on the same day for lipid profile levels (Abbott C4000, USA) and the other sample containing whole blood was used for the measurement of HbA1c

**Laboratory investigations:**
- Estimation of Glycated haemoglobin (HbA1c) in blood.
- Lipid profile: Total cholesterol (TC) was measured by cholesterol oxidase, triglyceride (TG) by glycerol oxidase-peroxidase, HDL by enzymatic assay. LDL-cholesterol was measured according to Friedewald formula. LDL was calculated as follows: LDL = TC - (HDL + TG/5).

**STATISTICAL ANALYSIS**

The data collection included demographics, medical diagnoses, HbA1c levels and lipid profile. Statistical analysis was done using SPSS for windows, Version 11.0. SPSS Inc. software. Data collected were compiled and were presented as mean ± standard deviation analyzed using statistical tests, \( P \leq 0.05 \) was considered statistically significant.

**RESULTS**

A total of 110 T2DM patients participated in the study, this included 55 T2DM patients with DFU and 55 patients without DFU. We compared the level of HbA1c and lipid profile in T2DM patients with diabetic foot ulcer and patients without DFU. Based on the length of the disease, 47% of the patients had diabetes for 10 years, 40% for 10–20 years, and 13% for 20 years. In addition, 79% and 77% of total patients with DFU were found male and aged more than 55 years respectively. The data analysis revealed that, the HbA1c, Cholesterol, LDL and TG levels are significantly higher in DFU-patients (8.83%, 225.76 mg/dl, 143.79 mg/dl and 175.10 mg/dl respectively) than that of patients without DFU (6.42%, 171.18 mg/dl, 106.65 mg/dl, 126.07 mg/dl respectively). Values of HDL are significantly higher in patients without DFU as compared with patients of DFU. Table No 1.

It was found that approximately 78% foot ulcer patients have HbA1c levels >7%. Unlike the DFU-patients, 79% of patients without DFU have HbA1c level controlled.

**DISCUSSION**

HbA1c has gained special attention of researchers and has been extensively studied in relation with diabetic foot ulcers, gangrene, and limb amputation. Our study showed a significant increase in HbA1c level and lipid parameters in patients with diabetic foot ulcer when compared to control group and it was found 78% and 75% of total patients with DFU were male and aged more than 55 respectively, which indicates that male persons and patient aged more than 50 are at the greater risk of foot ulcer. Further, the study evaluated the high percentage (78%) of DFU patients with HbA1c > 7. Poor glycemic control in the body results in diminished oxygen and nutrient supply to the ulcer area and compromised immune system due to impaired chemotaxis.

**Table-1:** Mean values of HbA1c, Lipid profile in patients with and without DFU (Mean ± SD).

| Parameters          | Patient with Diabetic Foot Ulcer | Patient without Diabetic Foot ulcer | P value |
|---------------------|----------------------------------|------------------------------------|---------|
| HbA1c (%)           | 8.83 ± 1.68                      | 6.42 ± 1.21                        | <0.001* |
| Cholesterol (mg/dl) | 225.76 ± 38.19                   | 171.18 ± 28.21                     | <0.001* |
| HDL cholesterol     | 39.27 ± 8.0                      | 42.94 ± 5.57                       | <0.001* |
| HDL-C (mg/dl)       | 143.79 ± 44.82                   | 106.65 ± 32.63                     | <0.001* |
| LDL cholesterol     | 175.10 ± 27.74                   | 126.07 ± 23.20                     | <0.001* |
| LDL-C (mg/dl)       |                                  |                                    |         |
| TGs (mg/dl)         |                                  |                                    |         |

Note: *Significant p-value.

Abbreviations: HbA1c- Glycated haemoglobin; LDL-C- Low-density lipoprotein cholesterol; HDL-C- High-density lipoprotein cholesterol; TG’s- Triglycerides.
and phagocytosis. These findings are in accordance with those of other studies, which report 86% of DFU patients have the HbA1c = 8.86%. The finding can be correlated to the fact that diabetic mellitus being a metabolic disorder causes altered protein and lipid metabolism and there by abnormal granulation tissue formation. Findings of our study are in accordance with Goldin A. et al who indicated that persistently high blood glucose levels in the body end up in uncontrolled binding of sugars to protein or lipid covalently without any normal glycosylation enzymes. The accumulation of these products called advanced glycation end product (AGEs) over the surface of cell membranes on extracellular matrix proteins collagen, vitronectin and laminin results in increased stiffness and increased synthesis of granulation tissue.

HbA1c is considered as a diagnostic marker for diagnosis of diabetes by American Diabetes Association and World Health Organization and is a good marker for glycemic control as its levels indicate the average level of blood sugar over past 2 to 3 months. HbA1c is not only a reliable glycemic index but its higher values can also be used as a sign of dyslipidemia. A 1% drop in the HbA1c level decreases the 40% risk of microvascular complications. A valid association has been established between HbA1c levels and various complications in diabetic patients such as diabetic retinopathy and foot ulcers. The healing time for foot ulcers in patients with lower HbA1c was shorter than patients with higher values. Clinical study reported by Markuson et al reported HbA1c as a significant determinant of foot ulcer healing in diabetic patients.

CONCLUSION

As diabetic foot ulcer is a major disabling complication of Diabetes Mellitus and often precedes lower extremity amputation, we conclude that HbA1c level should be maintained in normal range and regulating it is imperative for avoiding T2DM complications.

REFERENCES

1. Hussain A, Ali I, Ijaz M, et al. Correlation between hemoglobin A1c and serum lipid profile in Afghan patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia. Ther Adv Endocrinol Metab. 2017;8:51–57.
2. International Diabetes Federation. IDF Diabetes Atlas. 8th ed; 2017. Available from: http://www.diabetesatlas.org/. Accessed August 8, 2019.
3. Assaad-Khalil SH, Zaki A, Abdel Rehim A, Megallaa MH, Gaber N, Gamal H, et al. Prevalence of diabetic foot disorders and related risk factors among Egyptian subjects with diabetes. Prim Care Diabetes 2015;9:297-303.
4. Al-Wakeel JS, Hammad D, Al Suwaidi A, Mitwalli AH, Memon NA, Sulimani F, et al. Microvascular and macrovascular complications in diabetic nephropathy patients referred to nephrology clinic. Saudi J Kidney Dis Transpl 2009;20:77-85.
5. Boulton, A.J.M., L. Vileikyte, Ragnarson-Tennvall and J. Apelqvist. The global burden of diabetic [19-22]. foot disease. Lancet. 2005;366: 1719-24.
6. Kleopatra, A. and J. Doupis. Management of Diabetic Foot Ulcers. Diabetes Ther. 2012;3: 4.
7. Li, X., T. Xiao, Y. Wang, H. Gu, Z. Liu, Y. Jiang, Y. Liu, Z. Lu, X. Yang, Y. Lan and Z. Xu. Incidence, risk factors for amputation among patients with diabetic foot ulcer in a Chinese tertiary hospital. Diabetes Research and Clinical Practice, 2011;93: 26-30.
8. Stettler C, Allemann S, Juni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152:27–38.
9. Kranenburg G, van der Graaf Y, van der Leeuw J, et al. The relation between HbA1c and cardiovascular events in patients with type 2 diabetes with and without vascular disease. Diabet Care. 2015;38:1930–1936.
10. World Medical Association declaration of Helsinki. Ethical Principles for Medical Research involving Human subjects. World Medical Association available from: http://www.wma.net/e/policy/b3html. Accessed on 16.11.2016.
11. Abraham EC, Huff TA, Cope ND, Wilson JB Jr., Branson ED Jr., Huisman TH. Determination of the glycosylated hemoglobin (HB Al) with a new microcolumn procedure. Suitability of the technique for assessing the clinical management of diabetes mellitus. Diabetes 1978;27:931-7.
12. Assmann G, Schriewer H, Schmitz G, Hägele EO. Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem 1983;29:2026-30.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
14. WHO Guidelines Approved by the Guidelines Review Committee. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO consultation. Geneva: World Health Organization; 2011.
15. C.M.M. Hasan, R. Parial, M.M. Islam, M.N.U. Ahmad and Amir Kasru. Association of HbA1c, Creatinine and Lipid Profile in Patients with Diabetic Foot Ulcer. Middle-East Journal of Scientific Research 2013;16: 1508-1511.
16. Mueen Uddin, Asadullah Shah, Raed Alsaqour and Jamshed Memon. Measuring Efficiency of Tier Level Data Centers to Implement Green Energy Efficient Data Centers, Middle-East Journal of Scientific Research, 2013;15: 200-207.
17. Zubair M, Malik A, Ahmad J. Glycosylated hemoglobin in diabetic foot and its correlation with clinical variables in a north Indian tertiary care hospital. J Diabetes Metab 2015;6:7.
18. Shahbazian H, Yazdanpanah L, Latifi SM. Risk assessment of patients with diabetes for foot ulcers according to risk classification consensus of International Working Group on Diabetic Foot (IWGDF). Pak J Med Sci 2013;29:730-4.
19. Goldin, A., J.A. Beckman, A.M. Schmidt and M.A. Creager. Advanced glycation end products: sparking the
development of diabetic vascular injury. Circulation. 2006;114: 597-605.
20. American Diabetes Association. Standards of medical care in diabetes–2006. Diabet Care. 2006;29:S4–S42.
21. Markuson M, Hanson D, Anderson J, Langemo D, Hunter S., Thompson P, et al. The relationship between hemoglobin A(1c) values and healing time for lower extremity ulcers in individuals with diabetes. Adv Skin Wound Care 2009;22:365-72.

Source of Support: Nil; Conflict of Interest: None
Submitted: 15-05-2020; Accepted: 30-05-2020; Published: 24-06-2020